Alkyl Amines Chemicals Ltd

- Planned CAPEX of approximately Rs. 1.7 billion for the current year and next year. - New aliphatic amines project under construction at Kurkumbh with a project cost of around Rs. 350-360 crore, expected to be commissioned by end of 2022. - Continuous debottlenecking and brownfield expansion of DMA HCL capacity ongoing, resulting in yearly capacity increases. - Recently commissioned a new Acetonitrile plant (Rs. 160 crore investment) which has started production. - Other small projects including a hydrogen plant are due for commissioning within the next 6 months. - Looking for additional land parcels of 70-150 acres for future expansions beyond September 2023, but currently have sufficient land until that time. - Future investments also planned based on R&D developments to introduce new products aligning with COVID treatment drug requirements.

- The company experienced a challenging first half of the year but is optimistic about better performance in upcoming months. - New projects like the Acetonitrile plant (starting production shortly) and the higher amines plant in Kurkumbh (expected by end of 2022) will contribute to revenue growth. - Expansion plans include a Rs. 600-700 crore CAPEX over the next 2-3 years to increase capacities. - Aliphatic amines capacity is expected to increase by about 30% after the Kurkumbh plant comes on stream. - Acetonitrile capacity will increase from about 12,000 tons to 30,000 tons per year. - Exports have been strong recently and are expected to play a larger role in turnover going forward. - The government PLI scheme and efforts to diversify supply chains away from China are expected to positively impact the pharma-related demand. - Overall, the company expects improved sales growth driven by capacity expansions and favorable market dynamics.

- Management expects improved performance in coming months after a challenging first half of FY22. - New Acetonitrile plant commissioning starting production adds to topline and bottom line. - Higher Amines plant at Kurkumbh (one of the largest globally) to come on stream end of 2022, increasing aliphatic amines capacity by ~30%. - Ongoing capacity expansions and debottlenecking of DMA HCL to steadily increase output. - CAPEX of approximately Rs. 350-360 crore for higher amines and Rs. 170-200 crore annually over next two years planned for expansion and new projects. - Expected benefit from stabilized raw material prices after peak inflationary pressures. - Export volumes expected to increase, supported by new capacities and easing logistics. - Positive industry outlook driven by Pharma sector growth, supply chain diversification away from China, and government initiatives like PLI scheme. - Overall, earnings and profits are expected to grow as new capacities ramp up and price stabilization occurs.

The transcript and document pages provided do not explicitly mention the current or expected order book or pending orders status for Alkyl Amines Chemicals Limited. However, relevant insights include: - The company is experiencing a challenging first half of the year but expects better performance in upcoming months. - New projects like the Acetonitrile plant (commissioning started) and Higher Amines plant (expected by end of 2022) indicate ongoing expansion and future order potential. - Supply chain issues in Pharma and Agro sectors caused about 10% volume loss, expected to recover as disruptions settle. - Raw material price volatility has impacted margins but is expected to stabilize, providing better operating conditions. - Export demand is strengthening, with plans for increased exports due to new plant capacities. No direct data on order book or pending orders was disclosed in the call or enclosed documents.

- No explicit mention of any current or planned fundraising through debt or equity is indicated in the provided transcript. - The company is undertaking CAPEX of around Rs. 170-200 crore this year and next year, funded likely through internal accruals or existing resources. - The management discusses ongoing and future expansion plans, including setting up new plants but does not mention raising funds from debt or equity markets. - Land acquisition for future expansions is considered but no reference to fundraising is made. - Overall, the transcript focuses primarily on operational updates, raw material prices, and capacity expansions without discussing fundraising activities.